System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Nebojsa Lalic is an expert in Endocrinology at Klinički centar Srbije (Serbia). As of August 2026, ScienceLeadR ranks Nebojsa Lalic in the top 1% of experts worldwide for Diabetes Mellitus and Glucose Metabolism Disorders. Nebojsa Lalic has authored 214 publications, the most recent in 2026, and is an investigator in 15 clinical trials, 1 of them ongoing. SLR score: 670 (community average: 125). How the SLR is computed.

LeadR Profile

Nebojsa Lalic Klinički centar Srbije Serbia
670 ScienceLeadR Reputation 670

Unlock

Register Login
Network Map

Endocrinology

Subspecialties: Cardiology - Internal Medicine - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1999 - 2026
Source: PubMed

University of Belgrade

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 214

Citations

Citations: 27 369 1st author: 16 Last author: 35 Unique author: 5

Main journals

Cardiovasc Diabetol 16
Diabetes Res Clin Pract 15
Diabetes Ther 12
N Engl J Med 9
Transplant Proc 8

Best Journals

N Engl J Med 8
Lancet 2
Eur Heart J 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
ESC Guidelines on prevention and rehabilitation in coronary heart disease and current practice: the EUROASPIRE VI survey.
PMID 42666091 — heart diseases, heart, cardiac rehabilitation, rehabilitation, cardiology, secondary prevention, coronary disease, risk factors		Eur Heart J Top journal20260
From global guidelines for cardio-kidney-metabolic diseases management to national implementation: perspectives from the guideline workshop taskforce.
PMID 41731496 — metabolic diseases, kidney, diabetes complications		Cardiovasc Diabetol20260
Gestational Diabetes Associated with Postpartum NAFLD Risk Meta-Analysis: Evidence for Sustained Metabolic Dysfunction Beyond Pregnancy.
PMID 41682890 — diabetes mellitus, diabetes, gestational, pregnancy, non-alcoholic fatty liver disease, liver, postpartum period		J Clin Med20260
Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial.
PMID 41627802 — diabetes mellitus, kidney diseases, heart failure, internal medicine, heart, kidney, drug-related side effects and adverse reactions, history, diabetes mellitus, type 2, semaglutide		JAMA Intern Med20260
Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial.
PMID 41380027 — diabetes mellitus, kidney, therapeutics, diabetes mellitus, type 2, semaglutide		Diabetes Care20260

Clinical Studies 15

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

Phase 3 10
N/A 4
Phase 2 1

By status:

Completed 10
Unknown 2
Active not recruiting 1
Recruiting 1
Terminated 1

By type:

Interventional 14
Observational 1

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 0
multicentric5to9 0
multicentricup10 12

Main Topics

Cohort/Consortium Investigators 2

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Research Study on Whether Semaglutide Works in People With Non alcoholic Steatohepatitis (NASH)
NCT04822181 — liver diseases, skin, non-alcoholic fatty liver disease, liver, alcoholics, research, fatty liver, fatty liver, alcoholic, semaglutide		Phase 3Active not recruiting2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS